February 23, 2017 / 1:02 PM / 6 months ago

BRIEF-Novartis says Zykadia drug receives FDA priority review

Feb 23 (Reuters) - Novartis AG :

* Novartis drug Zykadia receives FDA priority review for first-line use in patients with ALK+ metastatic NSCLC

* Novartis AG - FDA also granted breakthrough therapy designation to Zykadia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below